Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027
Schizophrenia Market Scenario
Schizophrenia Market is projected to reach USD 7.2 Billion in 2018 and expected to register a 2.5% CAGR during the forecast period. Schizophrenia is a long-term mental disorder involving a breakdown in the relation between thought, emotion, and behavior. Although the course of schizophrenia varies among individuals, it is typically persistent and can be both severe and disabling.
Key Players
Some of key the players in the market are Minerva Neurosciences (U.S.), Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K).
Segmentation
The global schizophrenia market is segmented on the basis of by diagnosis, by treatment type, and by end user.
On the basis of the diagnosis, it is segmented into blood and urine tests, brain imaging, vision testing, and others.
On the basis of the treatment type, it is segmented into surgery, radiation therapy, medications, and others.
On the basis of the end user, it is segmented into hospitals, clinics, diagnostic centers, rehabilitation centers and others.
Regional Outlook:
The Americas dominate the global schizophrenia market owing to the presence of awareness of healthcare, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global schizophrenia market as result of increasing focus of various government agencies on the treatment of mental illness disease such as schizophrenia. Moreover, the growing public awareness about schizophrenia likely to boost the Europe market.
Asia Pacific is the fastest growing schizophrenia market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in India, Iran, Pakistan, Tanzania, over the forecasted period. Additionally, WHO initiative for training primary health-care personnel, providing access to essential drugs, and supporting families in providing home care lead the market growth of the schizophrenia in the region.
The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market.
Intended Audience
- Companies into Schizophrenia
- Research and Development (R&D) Companies
- Independent Research Laboratories
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Brows Complete Research Report@ https://www.marketresearchfuture.com/reports/schizophrenia-market-1625
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
